- Elucidates the benefits and pitfalls of current clinic FDG PET
- Enriches understanding of moving radiopharmaceuticals from the workbench to the clinic
- Provides translational research for clinical discussions about pathway directed systems imaging which correlates with genomic and proteomic expressions
This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed.
Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body imageupon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome.
This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imagingscientists, pharmaceutical developers, physicists, and support staff.
Dr. Tomio Inoue
President, Yokohama City University Medical Center
Dr. David J. Yang
Professor and Section Chief, Radiotheranostic Section,
Department of Cancer System Imaging,
Division of Diagnostic Imaging,
MD Anderson Cancer Center,
Consultant and Professor at The University of Tennessee Health Science Center,
Vice-president for Vyripharm Biopharmaceuticals
Dr. Gang Huang
Chairman, Institute of Nuclear Medicine,
Shanghai JiaoTong University School of Medicine